Literature DB >> 15103452

Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden.

John A Kanis1, Olof Johnell, Anders Oden, Frederik Borgstrom, Helena Johansson, Chris De Laet, Bengt Jönsson.   

Abstract

The aim of this study was to determine the threshold of fracture probability at which interventions became cost-effective in men and women, based on data from Sweden. We modeled the effects of a treatment costing $500 per year given for 5 years that decreased the risk of all osteoporotic fractures by 35% followed by a waning of effect for a further 5 years. Sensitivity analyses included a range of effectiveness (10-50%) and a range of intervention costs ($200-500/year). Data on costs and risks were from Sweden. Costs included direct costs, but excluded indirect costs due to morbidity. A threshold for cost-effectiveness of approximately $45,000/QALY gained was used. Cost of added years was included in a sensitivity analysis. With the base case ($500 per year; 35% efficacy) treatment in women was cost-effective with a 10-year hip fracture probability that ranged from 1.2% at the age of 50 years to 7.4% at the age of 80 years. Similar results were observed in men except that the threshold for cost-effectiveness was higher at younger ages than in women (2.0 vs 1.2%, respectively, at the age of 50 years). Intervention thresholds were sensitive to the assumed effectiveness and intervention cost. The exclusion of osteoporotic fractures other than hip fracture significantly increased the cost-effectiveness ratio because of the substantial morbidity from such other fractures, particularly at younger ages. We conclude that the inclusion of all osteoporotic fractures has a marked effect on intervention thresholds, that these vary with age, and that available treatments can be targeted cost-effectively to individuals at moderately increased fracture risk.

Entities:  

Mesh:

Year:  2004        PMID: 15103452     DOI: 10.1007/s00198-004-1623-4

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  66 in total

1.  Effect and offset of effect of treatments for hip fracture on health outcomes.

Authors:  B Jonsson; J Kanis; A Dawson; A Oden; O Johnell
Journal:  Osteoporos Int       Date:  1999       Impact factor: 4.507

2.  Accounting for future costs in medical cost-effectiveness analysis.

Authors:  D Meltzer
Journal:  J Health Econ       Date:  1997-02       Impact factor: 3.883

3.  The burden of osteoporotic fractures: a method for setting intervention thresholds.

Authors:  J A Kanis; A Oden; O Johnell; B Jonsson; C de Laet; A Dawson
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

4.  The Sheffield table for primary prevention of coronary heart disease: corrected.

Authors:  L E Ramsay; I U Haq; P R Jackson; W W Yeo
Journal:  Lancet       Date:  1996-11-02       Impact factor: 79.321

5.  Preference for fractures and other glucocorticoid-associated adverse effects among rheumatoid arthritis patients.

Authors:  L A Merlino; I Bagchi; T N Taylor; P Utrie; E Chrischilles; W Sumner; A Mudano; K G Saag
Journal:  Med Decis Making       Date:  2001 Mar-Apr       Impact factor: 2.583

6.  Excess mortality after hospitalisation for vertebral fracture.

Authors:  John A Kanis; Anders Oden; Olof Johnell; Chris De Laet; Bengt Jonsson
Journal:  Osteoporos Int       Date:  2003-11-04       Impact factor: 4.507

7.  The components of excess mortality after hip fracture.

Authors:  J A Kanis; A Oden; O Johnell; C De Laet; B Jonsson; A K Oglesby
Journal:  Bone       Date:  2003-05       Impact factor: 4.398

8.  Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial.

Authors:  John A Kanis; Olof Johnell; Dennis M Black; Robert W Downs; Somnath Sarkar; Thomas Fuerst; Roberta J Secrest; Imre Pavo
Journal:  Bone       Date:  2003-09       Impact factor: 4.398

9.  The apparent incidence of hip fracture in Europe: a study of national register sources.

Authors:  O Johnell; B Gullberg; E Allander; J A Kanis
Journal:  Osteoporos Int       Date:  1992-11       Impact factor: 4.507

10.  Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture.

Authors:  J A Kanis; O Johnell; B Gullberg; E Allander; G Dilşen; C Gennari; A A Lopes Vaz; G P Lyritis; G Mazzuoli; L Miravet
Journal:  BMJ       Date:  1992-11-07
View more
  39 in total

1.  Requirements for DXA for the management of osteoporosis in Europe.

Authors:  J A Kanis; O Johnell
Journal:  Osteoporos Int       Date:  2004-12-24       Impact factor: 4.507

2.  The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.

Authors:  F Borgström; O Ström; J Coelho; H Johansson; A Oden; E V McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2009-06-30       Impact factor: 4.507

Review 3.  Bone fragility in men--where are we?

Authors:  E Seeman; G Bianchi; S Khosla; J A Kanis; E Orwoll
Journal:  Osteoporos Int       Date:  2006-08-01       Impact factor: 4.507

4.  Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model.

Authors:  W Ni; Y Jiang
Journal:  Osteoporos Int       Date:  2016-08-31       Impact factor: 4.507

5.  The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis.

Authors:  F Borgström; O Ström; J Coelho; H Johansson; A Oden; E McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2009-06-10       Impact factor: 4.507

6.  Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA.

Authors:  B Dawson-Hughes; A N A Tosteson; L J Melton; S Baim; M J Favus; S Khosla; R L Lindsay
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

7.  Cost-effective osteoporosis treatment thresholds: the United States perspective.

Authors:  A N A Tosteson; L J Melton; B Dawson-Hughes; S Baim; M J Favus; S Khosla; R L Lindsay
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

8.  The effects of a FRAX revision for the USA.

Authors:  J A Kanis; H Johansson; A Oden; B Dawson-Hughes; L J Melton; E V McCloskey
Journal:  Osteoporos Int       Date:  2009-08-25       Impact factor: 4.507

9.  [Treatment of osteoporosis according to the "European Guidance 2008". Fracture-oriented--economical--cost-effective].

Authors:  R Bartl
Journal:  Internist (Berl)       Date:  2008-09       Impact factor: 0.743

Review 10.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women.

Authors:  J A Kanis; N Burlet; C Cooper; P D Delmas; J-Y Reginster; F Borgstrom; R Rizzoli
Journal:  Osteoporos Int       Date:  2008-02-12       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.